We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Vasogen Inc (NYSE:MEW - TSE:VAS) Immune Modulation Therapies
An SI Board Since February 2000
Posts SubjectMarks Bans Symbol
26 5 0 MEW
Emcee:  Smacs Type:  Unmoderated
Vasogen has been touted by analysts as one of the most promising Biotechs in Canada with 3 products currently in clinical trials and another two only months away. That will put them in a very promising position with 5 products in clinical trials at one time! With an unbelieveable roster on their Scientific Advisory Panel and extremely positive results so far in both cardiovascular and immuno products, the future looks great for Vasogen.

Corporate Profile (from their website)

Vasogen Inc. is focused on the development and commercialization of immune modulation therapies to advance the treatment of cardiovascular, autoimmune and related inflammatory diseases. These therapies utilize components derived from a sample of a patient's own blood that has been modified by physicochemical biological modifiers. Research has shown that returning modified cellular and extracellular blood components by intra-muscular injection down-regulates self-destructive immune system activity, resulting in lower levels of inflammation, less tissue damage, and a reduction in disease. The Company has immune modulation therapies in development for the treatment of cardiovascular and autoimmune disease, and for the prevention or amelioration of ischemia/reperfusion injury. Vasogen is also developing a process to prevent Graft-versus-Host Disease, a life threatening complication of bone marrow transplantation.

Delivered by a platform medical device technology, Vasogen's therapies are designed to target fundamental disease causing processes more effectively while causing fewer side effects than current therapies. In collaboration with leading university centers, the Company has an active research and development program for new products. The Company controls the development and manufacture of its technologies for use in research and development activities and continues to advance its product development program to support future commercial scale production. The Company's policy is to secure intellectual property protection on inventions, technology, and improvements that are important to the development of its business and with respect to the application of its immune modulation therapies to the treatment of a number of disease indications.

The Company intends to commercialize its immune modulation therapies by partnering with established health care companies.
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
26There's a more active VSGN thread here: Subject 12072DewDiligence_on_SI-8/30/2005
25Looks like this blow up todayDavid Culver-8/30/2005
24Interesting article about using modified blood in New Scientist.http://www.newscStephen O-11/27/2003
23Not sure but I believe around the summer or next fall. We have a bit of waiting David Culver-11/24/2003
22Anybody know when phase 3 will be overKeith Fauci-11/24/2003
21What are you doing here? vsvKeith Fauci-9/17/2003
20Nice move today we are on our way to $10.00David Culver-9/16/2003
19Vasogen Inc VAS SharCal Gary-5/30/2002
18Vasogen raises $25-million through financing VasCal Gary-5/28/2002
17Vasogen arranges $17-million bought-deal financing Vasogen Inc VAS Shares issuCal Gary-5/7/2002
16Vasogen indentifies best psoriasis treatment schedule VasCal Gary-3/14/2002
15Nice to see some action here with the results released a couple of weeks ago I fDavid Culver-3/9/2002
14TD, Past tense is more than correct. Archived a couple of things without doingtuck-3/9/2002
13Tuck, I see you follow or followed this stock....I understand they will be releaArthur Radley-3/8/2002
12>>TORONTO, Sept. 13 /PRNewswire/ - William R. Grant, Chairman, and David Etuck-9/13/2001
11I am wondering: did he tell it in the interview to have an opportunity to unloaNikole Wollerstein-2/20/2001
10This is the link for anybody interested in the whole article: thestreet.comtom pope-2/17/2001
9From the end of an interview with a Merrill money manager in TSC >><i&tom pope-2/17/2001
8Anybody here? Vasogen becomes a player in the CLL market, which they estimate ttuck-1/9/2001
7Vasogen Added to the TSE 300 Composite Index Sep 26, 2000 Toronto, Ontario VSmacs-9/26/2000
6 Wednesday March 15, 9:10 am Eastern Time Company Press Release: Vasogen ReportSmacs-3/16/2000
5 Vasogen Inc. 2155 Dunwin Drive, Suite 10 Mississauga, ON, Canada L5L 4M1 tel: Smacs-3/9/2000
4 Just found this, it's a couple of days old however. VASOGEN INC: FDA Grantbrb-2/23/2000
3 Ah! Here's the report I was looking for yesterday. Long read...but well worSmacs-2/18/2000
2 Joseph! You're right on the money with BOTH stocks. Vasogen is garnering alSmacs-2/17/2000
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):